Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

Mostrar otras versiones (1)

BACKGROUND: Hyaluronan accumulation in tumour stroma is associated with reduced survival in preclinical cancer models. PEGPH20 degrades hyaluronan to facilitate tumour access for cancer therapies. Our objective was to assess safety and antitumour activity of PEGPH20 in patients with advanced solid t...

Descripción completa

Detalles Bibliográficos
Autores principales: Infante, Jeffrey R, Korn, Ronald L, Rosen, Lee S, LoRusso, Patricia, Dychter, Samuel S, Zhu, Joy, Maneval, Daniel C, Jiang, Ping, Shepard, H Michael, Frost, Gregory, Von Hoff, Daniel D, Borad, Mitesh J, Ramanathan, Ramesh K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785735/
https://www.ncbi.nlm.nih.gov/pubmed/28949957
http://dx.doi.org/10.1038/bjc.2017.327
Mostrar todas las versiones(2)

Ejemplares similares